| Host: | Mouse |
| Applications: | WB/IHC-P/ICC/IF/ELISA |
| Reactivity: | Vertebrates |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | Mouse monoclonal anti-IDH1-R132P Mutant for use in WB, IHC-P, ICC, IF and ELISA in Vertebrates samples. Datasheet included with dilution recommendations, and related reagents. |
| Clonality : | Monoclonal |
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Formulation: | Liquid in PBS (without Mg2+ and Ca2+) , pH 7.4, 150 mM NaCl, 50% glycerol |
| Purification: | Purified from ascites |
| Dilution Range: | WB-1:100-1:1000IHC-P-1:50-1:100ICC/IF-1:50-1:100ELISA-1:1000-1:5000 |
| Storage Instruction: | Store at-20°C. Avoid freeze/thaw cycles. |
| Immunogen: | A synthetic peptide from the internal region of IDH1 which includes the mutation of R132P, human origin. |
| Background | Isocitrate dehydrogenases (IDH) catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors. |
Information sourced from Uniprot.org